BioNTech (NASDAQ:BNTX) Announces Earnings Results

Key Points

• BioNTech reported ($2.26) EPS, beating estimates by $0.26, but revenue of $136.6 million missed the $207.4 million consensus and was down 35.4% year‑over‑year, leaving the company with negative margins and ROE.
• The company is pivoting to a tumor‑centric, combination‑first oncology strategy with plans for more than 17 late‑stage/pivotal readouts through 2030 (including five in 2026), and early data on pumitamab and gotistobart showed encouraging responses though pivotal validation is still required.
• BioNTech ended Q1 with EUR 16.8 billion in cash/securities, reaffirmed 2026 guidance and announced an opportunistic $1 billion ADS buyback, while planning manufacturing consolidation affecting ~1,800 roles to target about EUR 500 million in annual savings, posing near‑term execution risk.

BioNTech (NASDAQ:BNTX - Get Free Report) issued its earnings results on Tuesday. The company reported ($2.26) EPS for the quarter, topping analysts' consensus estimates of ($2.52) by $0.26, FiscalAI reports. BioNTech had a negative net margin of 38.09% and a negative return on equity of 4.76%. The company had revenue of $136.59 million for the quarter, compared to the consensus estimate of $207.43 million. During the same period in the previous year, the firm earned ($1.73) earnings per share. BioNTech's quarterly revenue was down 35.4% compared to the same quarter last year.

Here are the key takeaways from BioNTech's conference call:

• BioNTech is pivoting to a tumor‑centric, combination‑first oncology strategy with a focus on high‑incidence cancers and aims for more than 17 late‑stage/pivotal readouts through 2030 and five additional late‑stage readouts in 2026, signaling large future catalyst potential.
• Early clinical data support the approach — pumitamab Phase I‑B/II‑A showed a 46% confirmed ORR (median PFS 13.6 months, median OS 27 months) and a 71% ORR in PD‑L1 high squamous NSCLC, underpinning the ongoing global Phase III ROSETTA LUNG‑02 program.
• Gotistobart’s non‑pivotal data are encouraging — PRESERVE‑003 interim showed a 54% reduction in risk of death versus docetaxel (HR 0.46) and a 12‑month PFS of 25% vs 0, but management notes the sample is small and requires validation in the pivotal stage later this year.
• Strong balance sheet and shareholder returns — BioNTech ended Q1 with EUR 16.8 billion in cash/securities, reaffirmed 2026 guidance (EUR 2.0–2.3bn revenues) and announced an opportunistic $1 billion ADS share buyback, supporting capital allocation alongside R&D investment.
• Management plans to consolidate manufacturing (potentially exiting sites in Idar‑Oberstein, Marburg and Singapore), affecting ~1,800 positions while targeting about EUR 500 million in recurring annual savings; near‑term execution risks and one‑time charges are possible even as long‑term efficiency improves.

BioNTech Trading Down 2.2%

Shares of BioNTech stock traded down $2.18 on Tuesday, reaching $97.17. The company had a trading volume of 229,062 shares, compared to its average volume of 1,079,016. The firm's 50 day moving average price is $97.52 and its two-hundred day moving average price is $101.12. The firm has a market cap of $24.57 billion, a PE ratio of -18.51 and a beta of 1.36. BioNTech has a 52-week low of $79.52 and a 52-week high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.49 and a current ratio of 7.54.

Insider Buying and Selling at BioNTech

In related news, COO Sierk Poetting sold 50,000 shares of BioNTech stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the transaction, the chief operating officer owned 399,387 shares in the company, valued at approximately $44,156,226.72. The trade was a 11.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 19.20% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets grew its holdings in shares of BioNTech by 6.7% in the second quarter. BNP Paribas Financial Markets now owns 1,275,475 shares of the company's stock valued at $135,800,000 after purchasing an additional 80,005 shares in the last quarter. GSK plc acquired a new position in shares of BioNTech in the fourth quarter valued at approximately $84,711,000. Morgan Stanley grew its holdings in shares of BioNTech by 12.9% in the fourth quarter. Morgan Stanley now owns 680,669 shares of the company's stock valued at $64,800,000 after purchasing an additional 77,653 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of BioNTech by 344.4% in the third quarter. Bank of America Corp DE now owns 573,356 shares of the company's stock valued at $56,544,000 after purchasing an additional 444,332 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in shares of BioNTech by 2.9% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company's stock valued at $52,416,000 after purchasing an additional 13,788 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. The Goldman Sachs Group reaffirmed a "buy" rating on shares of BioNTech in a research note on Wednesday, March 11th. Truist Financial raised shares of BioNTech to a "strong-buy" rating in a research note on Wednesday, March 25th. Morgan Stanley boosted their price target on shares of BioNTech from $125.00 to $126.00 and gave the company an "overweight" rating in a research note on Friday, April 10th. Leerink Partners downgraded shares of BioNTech from an "outperform" rating to a "market perform" rating and set a $113.00 price target on the stock. in a research note on Monday, February 2nd. Finally, TD Cowen reduced their price target on shares of BioNTech from $116.00 to $94.00 and set a "hold" rating on the stock in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, BioNTech has a consensus rating of "Moderate Buy" and an average price target of $133.13.

About BioNTech

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.